Puma Biotechnology, Inc. (PBYI)
9.55
+0.14
(+1.49%)
USD |
NASDAQ |
Sep 04, 16:00
9.55
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Enterprise Value : 398.94M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 398.94M |
| September 03, 2026 | 391.79M |
| September 02, 2026 | 406.10M |
| September 01, 2026 | 388.72M |
| August 31, 2026 | 376.46M |
| August 28, 2026 | 373.90M |
| August 27, 2026 | 383.10M |
| August 26, 2026 | 379.01M |
| August 25, 2026 | 387.19M |
| August 24, 2026 | 376.97M |
| August 21, 2026 | 383.10M |
| August 20, 2026 | 376.46M |
| August 19, 2026 | 395.88M |
| August 18, 2026 | 383.10M |
| August 17, 2026 | 361.64M |
| August 14, 2026 | 362.15M |
| August 13, 2026 | 356.02M |
| August 12, 2026 | 365.73M |
| August 11, 2026 | 359.08M |
| August 10, 2026 | 355.00M |
| August 07, 2026 | 366.24M |
| August 06, 2026 | 325.87M |
| August 05, 2026 | 319.22M |
| August 04, 2026 | 309.52M |
| August 03, 2026 | 303.89M |
| Date | Value |
|---|---|
| July 31, 2026 | 316.16M |
| July 30, 2026 | 314.11M |
| July 29, 2026 | 310.03M |
| July 28, 2026 | 318.20M |
| July 27, 2026 | 319.22M |
| July 24, 2026 | 318.71M |
| July 23, 2026 | 320.25M |
| July 22, 2026 | 313.09M |
| July 21, 2026 | 349.38M |
| July 20, 2026 | 335.07M |
| July 17, 2026 | 346.82M |
| July 16, 2026 | 340.18M |
| July 15, 2026 | 340.69M |
| July 14, 2026 | 334.04M |
| July 13, 2026 | 323.82M |
| July 10, 2026 | 319.74M |
| July 09, 2026 | 314.63M |
| July 08, 2026 | 326.38M |
| July 07, 2026 | 317.69M |
| July 06, 2026 | 330.98M |
| July 02, 2026 | 333.02M |
| July 01, 2026 | 319.22M |
| June 30, 2026 | 325.36M |
| June 29, 2026 | 329.02M |
| June 26, 2026 | 324.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arcutis Biotherapeutics, Inc. | 2.877B |
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.189M |
| Revenue (Quarterly) | 56.50M |
| Total Expenses (Quarterly) | 48.31M |
| EPS Diluted (Quarterly) | 0.1557 |
| Gross Profit Margin (Quarterly) | 77.92% |
| Profit Margin (Quarterly) | 14.49% |
| Earnings Yield | 5.41% |
| Operating Earnings Yield | 6.19% |
| Normalized Earnings Yield | 5.407 |